menu
    • menu
    [{"orgOrder":0,"company":"CatalYm","sponsor":"Vesalius Biocapital III","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"CTL-002","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CatalYm","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"CatalYm \/ Vesalius Biocapital III","highestDevelopmentStatusID":"4","companyTruncated":"CatalYm \/ Vesalius Biocapital III"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CTL-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"CTL-002","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"GDF-15","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Brandon Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Series C Financing","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"CatalYm \/ Brandon Capital","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ Brandon Capital"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Nivolumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CatalYm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CatalYm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CatalYm \/ Not Applicable"},{"orgOrder":0,"company":"CatalYm","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series D Financing","leadProduct":"Nivolumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"CatalYm","amount2":0.14999999999999999,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"CatalYm \/ Canaan Partners","highestDevelopmentStatusID":"14","companyTruncated":"CatalYm \/ Canaan Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by CatalYm

    Menu

    CatalYm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Canaan Partners

                            Deal Size : $150.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            CatalYm cashes in on early-stage cancer data with $150M series D

                            Details : The Proceeds will expand CTL-002 (visugromab) late-stage clinical development into earlier lines of treatment in combination with nivolumab for the treatment of bladder cancer.

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Canaan Partners

                            Deal Size : $150.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Reports Lasting Responses in Late-Line NSCLC and Other Cancer Patients

                            Details : CTL-002 (visugromab) is a monoclonal antibody that neutralizes GDF-15 is being investigated in combination with nivolumab, a PD-1 inhibitor) in R/R non-small cell lung cancer (MIBC).

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2024

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in T...

                            Details : CTL-002 (Visugromab) is a monoclonal antibody that neutralizes the tumor-derived Growth Differentiation Factor-15 (GDF-15) in combination with neoadjuvant immunotherapy (nivolumab, aPD-1 inhibitor) in muscle invasive bladder cancer (MIBC).

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 26, 2023

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Brandon Capital

                            Deal Size : $51.8 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visu...

                            Details : The financing will support the continued, promising clinical development of its lead candidate, visugromab, a humanized monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 22, 2022

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Brandon Capital

                            Deal Size : $51.8 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the U....

                            Details : Visugromab, formerly known as CTL-002, is a monoclonal antibody that neutralizes GDF-15, a key immunosuppressor, which has been shown to prevent T cell migration into tumors, enabling cancerous cells to evade the immune system.

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 26, 2022

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Niv...

                            Details : Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 10, 2022

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-0...

                            Details : Visugromab, formerly known as CTL-002, is a humanized, monoclonal antibody designed to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15).

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 05, 2022

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Comple...

                            Details : The GDFATHER-2 trials, will evaluate safety and efficacy of CTL-002, mAB designed to neutralize tumor-produced GDF-15, at confirmed target dose in combination with nivolumab in tumor patients to anti-PD1/-L1 treatment and in one cohort that is anti-PD-1/...

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Visugromab,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTL-002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm Presents Updated Tolerability and Preliminary Pharmacodynamics Data from GDF-15 Targeting First-in-Hum...

                            Details : CatalYm’s CTL-002 demonstrate clinical proof-of-concept in multiple solid tumor indications which will expand the treatment for current and future immunotherapies. CTL-002 is a humanized, monoclonal antibody designed to neutralize the tumor-produced GD...

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 11, 2021

                            Lead Product(s) : CTL-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed

                            CatalYm

                            Germany arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CTL-002

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CatalYm To Present Update From GDF-15 Targeting First-in-Human I/O Clinical Trial in Plenary Session at AACR-N...

                            Details : CTL-002 is a humanized, monoclonal antibody designed to neutralize tumor-produced Growth Differentiation Factor-15 by enhancing infiltration of immune cells into tumor, improving both priming of T cells by dendritic cells and tumor killing by T cells and...

                            Brand Name : CTL-002

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 30, 2021

                            Lead Product(s) : CTL-002

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth